Sub-chronic (13-week) oral toxicity study in rats with recombinant human lactoferrin produced in the milk of transgenic cows

Food and Chemical Toxicology

Volumn 44, Issue 7, 2006, Pages 964-973

  Appel, M J ^a   van Veen, H A ^b   Vietsch, H ^b   Salaheddine, M ^b   Nuijens, J H ^b   Ziere, B ^b   de Loos, F ^b  

^a TNO   (Netherlands)

^b Pharming Group NV   (Netherlands)

Author keywords

Oral administration; Rats; Recombinant human lactoferrin; Repeated dose toxicity study

Indexed keywords

LACTOFERRIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY GROWTH; BODY WEIGHT; COGNITION; CONTROLLED STUDY; FEMALE; FLUID INTAKE; FOOD INTAKE; KIDNEY CONCENTRATING CAPACITY; NONHUMAN; OPHTHALMOSCOPY; PH MEASUREMENT; RAT; TOXICITY TESTING; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; BEHAVIOR, ANIMAL; BLOOD CELL COUNT; BLOOD CHEMICAL ANALYSIS; CATTLE; DRINKING; FEMALE; HUMANS; LACTOFERRIN; MILK; MOTOR ACTIVITY; NO-OBSERVED-ADVERSE-EFFECT LEVEL; ORGAN SIZE; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; SEX CHARACTERISTICS;

RATTUS NORVEGICUS;

EID: 33744901127     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fct.2005.11.012     Document Type: Article

References (28)

1. Anderson B.F., Baker H.M., Norris G.E., Rice D.W., and Baker E.N. Structure of human lactoferrin: crystallographic structure analysis and refinement at 2.8 Å resolution. J. Mol. Biol. 209 (1989) 711-734
2. Appelmelk B.J., An Y.Q., Geerts M., Thijs B.G., de Boer H.A., MacLaren D.M., de Graaff J., and Nuijens J.H. Lactoferrin is a lipid A-binding protein. Infect. Immun. 62 (1994) 2628-2632
3. Ashida K., Sasaki H., Suzuki Y.A., and Lönnerdal B. Cellular internalization of lactoferrin in intestinal epithelial cells. BioMetals 17 (2004) 311-315
4. van Berkel P.H.C., Welling M.M., Geerts M., van Veen H.A., Ravensbergen B., Salaheddine M., Pauwels E.K.J., Pieper F., Nuijens J.H., and Nibbering P.H. Large scale production of recombinant human lactoferrin in the milk of transgenic cows. Nature Biotechnol. 20 (2002) 484-487
5. Brines R.D., and Brock J.H. The effect of trypsin and chymotrypsin on the in vitro antimicrobial and iron-binding properties of lactoferrin in human milk and bovine colostrum. Unusual resistance of human apolactoferrin to proteolytic digestion. Biochim. Biophys. Acta 759 (1983) 229-235
6. Ellison III R.T., Giehl T.J., and La F.F. Damage of the outer membrane of enteric gram-negative bacteria by lactoferrin and transferring. Infect. Immun. 56 (1988) 2774-2781
7. Ellison III R.T., and Giehl T.J. Killing of gram-negative bacteria by lactoferrin and lysozyme. J. Clin. Invest. 88 (1991) 1080-1091
8. FDA. 1982. guidelines for the testing of food additives. Toxicological Principles for the Safety Assessment of Direct Food Additives and Color Additives Used in Food. US Food and Drug Administration Bureau of Foods.
9. He J., and Furmanski P. Sequence specificity and transcriptional activation in the binding of lactoferrin to DNA. Nature 373 (1995) 721-724
10. Kijlstra A., and Jeurissen S.H.M. Modulation of the classical C3 convertase of complement by tear lactoferrin. Immunology 47 (1982) 263-270
11. Lee W.J., Farmer J.L., Hilty M., and Kim Y.B. The protective effects of lactoferrin feeding against endotoxin lethal shock in germfree piglets. Infect. Immun. 66 (1998) 1421-1426
12. Legrand D., van Berkel P.H.C., Salmon V., van Veen H.A., Slomianny M.C., Nuijens J.H., and Spik G. The N-terminal Arg2, Arg3 and Arg4 of human lactoferrin interact with sulphated molecules but not with the receptor present on Jurkat human lymphoblastic T-cells. Biochem. J. 327 (1997) 841-846
13. Mann D.M., Romm E., and Migliorini M. Delineation of the glycosaminoglycan-binding site in the human inflammatory response protein lactoferrin. J. Biol. Chem. 269 (1994) 23661-23667
14. Moser V.C., Tilson H.A., Macphail R.C., Becking G.C., Cuomo V., Frantik E., Kulig B.M., and Winneke G. The IPCS collaborative study on neurobehavioral screening methods. II. Protocol design and testing procedures. Neurotoxicology 18 4 (1997) 929-939
15. Nichols B.L., McKee K.S., Henry J.F., and Putman M. Human lactoferrin stimulates thymidine incorporation into DNA of rat crypt cells. Pediatr. Res. 21 (1987) 563-567
16. Nuijens J.H., van Berkel P.H.C., and Schanbacher F.L. Structure and biological actions of lactoferrin. J. Mammary Gland Biol. Neoplasia 1 (1996) 285-295
17. OECD Guideline for the Testing of Chemicals 408 (adopted 21 September 1998).
18. Petschow B.W., and Talbott R.D. Response of bifidobacterium species to growth promoters in human and cow milk. Pediatr. Res. 29 (1991) 208-213
19. Reiter B., Brock J.H., and Steel E.D. Inhibition of Eschericia coli by bovine colostrum and post-colostral milk. II. The bacteriostatic effect of lactoferrin on a serum-susceptible and serum-resistant strain of E. coli. Immunology 28 (1975) 83-95
20. Sanchez L., Calvo M., and Brock J.H. Biological role of lactoferrin. Arch. Dis. Child 67 (1992) 657-661
21. Thomassen E.A., van Veen H.A., van Berkel P.H., Nuijens J.H., and Abrahams J.P. The protein structure of recombinant human lactoferrin produced in the milk of transgenic cows closely matches the structure of human milk-derived lactoferrin. Transgenic Res. 14 (2005) 397-405
22. Tomita M., Takase M., Wakabayashi H., and Bellamy W. Antimicrobial peptides of lactoferrin. Adv. Exp. Med. Biol. 357 (1994) 209-2018
23. van der Strate B.W.A., Beljaars L., Molema G., Harmsen M.C., and Meijer D.K.F. Antiviral activities of lactoferrin. Antiviral Res. 52 (2001) 225-239
24. van Veen H.A., Geerts M.E.J., van Berkel P.H.C., and Nuijens J.H. The role of N-linked glycosylation in the protection of human and bovine lactoferrin against tryptic proteolysis. Eur. J. Biochem. 271 (2004) 678-684
25. Yamauchi K., Toida T., Nishimura S., Nagano E., Kusuoka O., Teraguchi S., Hayasawa H., Shimamura S., and Tomita M. 13-week oral repeated administration toxicity study of bovine lactoferrin in rats. Food Chem. Toxicol. 38 (2000) 503-512
26. Zhang P., Sawicki V., Lewis A., Hanson L., Nuijens J.H., and Neville M.C. Human lactoferrin in the milk of transgenic mice increases intestinal growth in ten-day-old suckling neonates. Adv. Exp. Med. Biol. 501 (2001) 101-113
27. Ziere G.J., Bijsterbosch M.K., and van Berkel T.J. Removal of 14 N-terminal amino acids of lactoferrin enhances its affinity for parenchymal liver cells and potentiates the inhibition of beta-very low density lipoprotein binding. J. Biol. Chem. 268 (1993) 27069-27075
28. Zucali J.R., Broxmeyer H.E., Levy D., and Morse C. Lactoferrin decreases monocyte-induced fibroblast production of myeloid colony-stimulating activity by suppressing monocyte release of interleukin-1. Blood 74 (1989) 1531-1536